An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aerie Pharmaceuticals (NASDAQ: AERI) is set to release its third quarter 2021 financial results after market close on November 4, 2021. Following the release, a live conference call and webcast will take place at 5:00 p.m. Eastern Time to discuss these results and provide a general business update. Investors can access the webcast via the company's website or by calling in. Aerie focuses on developing therapies for open-angle glaucoma and ocular surface diseases, with products like Rhopressa and Rocklatan already on the market since 2018 and 2019, respectively.
Positive
None.
Negative
None.
DURHAM, N.C.--(BUSINESS WIRE)--
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, announced today that its third quarter 2021 financial results will be released after the market closes on Thursday, November 4, 2021. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
The live webcast and a replay may be accessed by visiting the Company’s website at http://investors.aeriepharma.com. Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (888) 734-0328 (U.S.) or (678) 894-3054 (international) to listen to the live conference call. The conference ID number for the live call is 4696924. Please dial in approximately 10 minutes prior to the call. Telephone replay will be available approximately two hours after the call. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international). The conference ID number for the replay is 4696924. The telephone replay will be available until November 12, 2021.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for the treatment of dry eye, wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.
Investors:
LifeSci Advisors on behalf of Aerie Pharmaceuticals, Inc. Hans Vitzthum hans@lifesciadvisors.com
(617) 430-7578
Source: Aerie Pharmaceuticals, Inc.
FAQ
When will Aerie Pharmaceuticals release its Q3 2021 financial results?
Aerie Pharmaceuticals will release its Q3 2021 financial results after the market closes on November 4, 2021.
What time is the Aerie Pharmaceuticals conference call?
The conference call for Aerie Pharmaceuticals will be held at 5:00 p.m. Eastern Time on November 4, 2021.
How can I listen to Aerie Pharmaceuticals' conference call?
You can listen to Aerie Pharmaceuticals' conference call by accessing their website or by calling (888) 734-0328 for U.S. or (678) 894-3054 for international listeners.
What is the focus of Aerie Pharmaceuticals?
Aerie Pharmaceuticals focuses on the discovery, development, and commercialization of therapies for treating open-angle glaucoma and ocular surface diseases.
